Prostate Cancer Genetic Risk Evaluation and Screening Study

Launched by MASSACHUSETTS GENERAL HOSPITAL · Nov 9, 2021

Keywords

ClinConnect Summary

The Prostate Cancer Genetic Risk Evaluation and Screening Study is looking to understand how men who are at high genetic risk for prostate cancer can be better identified and monitored. This includes men with specific genetic mutations, those with a strong family history of prostate cancer, and Black men with African ancestry. The study is also testing whether using MRI scans can help find prostate cancer earlier and more accurately in these high-risk groups. The researchers believe that these men may have a higher chance of developing aggressive types of prostate cancer compared to others.

To be eligible for this study, participants must be men aged 35 to 74 who do not currently have prostate cancer and are expected to live for at least another 10 years. They must either have a documented genetic mutation linked to prostate cancer, have a strong family history of the disease, or identify as Black American or Black Caribbean with African ancestry. Participants will undergo MRI scans to help screen for prostate cancer, which is a safe and non-invasive procedure. This study aims to improve early detection and better understand the genetic factors that contribute to prostate cancer risk.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Men 35-74 years old
• • No known diagnosis of prostate cancer
• • Life expectancy \>10 years
• • Meet cohort A, B, or C criteria
• • Cohort A: Documented pathogenic or likely pathogenic germline genetic mutation in a prostate cancer risk gene from a CLIA-certified laboratory (ATM, ATR, BRCA1, BRCA2, BRIP1, CHEK2, EPCAM, FANCA, GEN1, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, RAD51C, RAD51D, TP53)
• • Cohort B: A strong family history suggestive of high genetic risk for prostate cancer with negative clinical genetic testing
• • Cohort C: Individuals who self-identify as Black American or Black Caribbean with both parents and all four grandparents of Black/African ancestry
• Exclusion Criteria:
• • Prior diagnosis or treatment of prostate cancer
• • Inability to undergo prostate MRI
• • Inability to receive MRI contrast agent